U.S. Stock Insider Trading | Viatris disclosed 19 insider transactions on March 5

robot
Abstract generation in progress

On March 5, 2026, Viatris (VTRS) disclosed 19 insider trading transactions. Director Smith Scott Andrew sold 506.4k shares on March 4, 2026.

【Recent Insider Transactions】

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 5, 2026 Executive Mistras Theodora March 4, 2026 Sell 18.9k 14.71 277.3k
March 5, 2026 Executive Campbell Paul March 4, 2026 Sell 8,198 14.71 120.6k
March 5, 2026 Executive Le Goff Corinne March 4, 2026 Sell 17.7k 14.71 259.7k
March 5, 2026 Executive Enrietti Andrew March 3, 2026 Sell 54k 14.89 803.3k
March 5, 2026 Director Smith Scott Andrew March 4, 2026 Sell 39.8k 14.71 585.9k
March 5, 2026 Director Smith Scott Andrew March 3, 2026 Sell 567k 14.89 8.44M
March 5, 2026 Executive Campbell Paul March 3, 2026 Sell 83.3k 14.89 1.24M
March 5, 2026 Executive Enrietti Andrew March 4, 2026 Sell 6,458 14.71 95k
January 2, 2026 Executive Mistras Theodora January 1, 2026 Sell 14.6k 12.45 181.7k
September 12, 2025 Executive Le Goff Corinne September 11, 2025 Sell 7,032 10.25 72k

【Company Information】

Viatris Inc. was incorporated in Delaware on February 14, 2019. The company is a global healthcare company that believes it has a unique positioning to bridge the traditional gap between generic and branded drugs, combining the advantages of both to better meet healthcare needs worldwide. Viatris’s mission is to empower people around the world to live healthier lives at every stage of life, providing large-scale access services. Currently, it supplies high-quality medicines to approximately 1 billion patients globally each year, touching all moments of life—from birth to end-of-life, from acute to chronic diseases.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments